# Patient Protocol Audit - Step 3: Coverage Map

## Medications with Document Coverage

### ✅ LDA (Low-Dose Aripiprazole/Abilify)
**Coverage locations:**
- appendix-h-annotated-bibliography.tex
- ch25b-proposed-studies.tex
- ch14b-action-mild-moderate.tex
- ch18-emerging-therapies.tex
- ch15-medications-systems.tex
- ch21-clinical-trials.tex

**Action:** Add to appendix-i-a with patient-specific rationale

---

### ✅ Cerebokan (Ginkgo biloba)
**Coverage locations:**
- ch15-medications-systems.tex
- ch14a-urgent-action-severe.tex
- ch14i-clinical-brainstorm.tex

**Action:** Add to appendix-i-a with patient-specific rationale

---

### ✅ Levocetirizine (H1 antihistamine)
**Coverage locations:**
- appendix-h-annotated-bibliography.tex
- appendix-j-recommendations.tex
- ch19-integrative-approaches.tex

**Action:** Add to appendix-i-a with patient-specific rationale (mast cell activation)

---

### ✅ Ivabradine (heart rate control)
**Coverage locations:**
- appendix-h-annotated-bibliography.tex
- ch14b-action-mild-moderate.tex
- ch13-integrative-models.tex

**Action:** Add to appendix-i-a with patient-specific rationale (POTS/autonomic dysfunction)

---

### ✅ Cimetidine (H2 antihistamine)
**Coverage locations:**
- appendix-h-annotated-bibliography.tex
- ch05-subgroups.tex
- ch04-08-differential-diagnosis.tex

**Action:** Add to appendix-i-a with patient-specific rationale (histamine intolerance)

---

### ✅ Ketotifen (mast cell stabilizer)
**Coverage locations:**
- appendix-j-recommendations.tex
- appendix-h-annotated-bibliography.tex
- ch11-gut-microbiome.tex

**Action:** Add to appendix-i-a with patient-specific rationale (mast cell activation)

---

### ✅ Quviviq (Daridorexant - orexin antagonist)
**Coverage locations:**
- ch14b-action-mild-moderate.tex
- ch14a-urgent-action-severe.tex
- appendix-h-annotated-bibliography.tex

**Action:** Add to appendix-i-a with patient-specific rationale (sleep)

---

### ✅ Mestinon (Pyridostigmine - acetylcholinesterase inhibitor)
**Coverage locations:**
- appendix-h-annotated-bibliography.tex
- ch25b-proposed-studies.tex
- ch14b-action-mild-moderate.tex
- ch13-integrative-models.tex

**Action:** Add to appendix-i-a with patient-specific rationale (autonomic dysfunction, orthostatic intolerance)

---

## Supplements with Document Coverage

### ✅ Zinc
**Coverage locations:**
- appendix-i-c-case-analysis.tex
- appendix-i-b-clinical-findings.tex
- ch14b-action-mild-moderate.tex

**Action:** Add to appendix-i-a supplement section with patient-specific rationale

---

### ✅ Glutathione
**Coverage locations:**
- ch11-gut-microbiome.tex
- ch06-energy-metabolism.tex
- ch12-genetics-epigenetics.tex

**Action:** Add to appendix-i-a supplement section with patient-specific rationale (antioxidant, detoxification)

---

### ✅ PEA (Palmitoylethanolamide)
**Coverage locations:**
- ch25-translational-findings.tex
- ch14b-action-mild-moderate.tex
- ch14a-urgent-action-severe.tex
- ch15-medications-systems.tex (per Phase 2 integration)
- appendix-g-research-synthesis.tex

**Action:** Add to appendix-i-a supplement section with patient-specific rationale (pain, mast cell modulation)

---

### ✅ L-Arginine
**Coverage locations:**
- appendix-h-annotated-bibliography.tex
- ch11-gut-microbiome.tex
- ch04-07-novel-framework.tex
- ch13-integrative-models.tex
- ch14e-2025-research.tex

**Action:** Add to appendix-i-a supplement section with patient-specific rationale (NO production, vascular function)

---

### ✅ L-Citrulline
**Coverage locations:**
- ch13-integrative-models.tex
- ch05-subgroups.tex
- ch11-gut-microbiome.tex
- appendix-h-annotated-bibliography.tex
- ch14b-action-mild-moderate.tex
- ch18-emerging-therapies.tex

**Action:** Add to appendix-i-a supplement section with patient-specific rationale (NO production, arginine precursor)

---

### ✅ Devil's Claw (Harpagophytum procumbens)
**Coverage locations:**
- ch15-medications-systems.tex (per Phase 1 integration, line 663+)
- ch14i-clinical-brainstorm.tex

**Action:** Add to appendix-i-a supplement section with patient-specific rationale (pain, anti-inflammatory)

---

## Summary

**ALL 13 gap items have existing document coverage:**
- 8/8 medications covered ✅
- 5/5 supplements covered ✅

**Next step:** Add patient-specific rationale to appendix-i-a-medical-management.tex for each item, citing the existing document coverage for mechanism/evidence.